Gilead to buy Ouro Medicines for up to $2.2 billion Mar 23, 2026 06:30PM
Mizuho's Jared Holz: 'We still like the sector, despite some recent setbacks like QURE and others' Mar 9, 2026 07:39AM
TD Cowen Downgrades Arcellx Inc. (ACLX) to Hold Mar 2, 2026 05:30AM
Guggenheim Downgrades Arcellx Inc. (ACLX) to Neutral Feb 26, 2026 12:48AM
UBS Downgrades Arcellx Inc. (ACLX) to Neutral Feb 24, 2026 12:39AM
View Older Stories

Feb 24, 2026 12:38AM Stifel Downgrades Arcellx Inc. (ACLX) to Hold
Feb 23, 2026 01:13PM Evercore ISI Downgrades Arcellx Inc. (ACLX) to In Line
Feb 23, 2026 11:21AM H.C. Wainwright Downgrades Arcellx Inc. (ACLX) to Neutral
Feb 23, 2026 09:43AM William Blair Downgrades Arcellx Inc. (ACLX) to Market Perform
Feb 23, 2026 09:40AM Piper Sandler Downgrades Arcellx Inc. (ACLX) to Neutral
Feb 23, 2026 09:31AM Raymond James on Legend Biotech Corp. (LEGN): 'Arcellx Takeout Indicates Legend is Hugely Undervalued'
Feb 23, 2026 08:43AM Wells Fargo Downgrades Arcellx Inc. (ACLX) to Equal Weight
Feb 23, 2026 08:32AM Baird Downgrades Arcellx Inc. (ACLX) to Neutral
Feb 23, 2026 08:09AM Truist Securities Downgrades Arcellx Inc. (ACLX) to Hold
Feb 12, 2026 02:54AM Rothschild Redburn Downgrades Arcellx Inc. (ACLX) to Neutral
Feb 9, 2026 07:26AM Arcellx (ACLX) Reiterated at Buy by Stifel: Still 'a Core SMid-Cap Holding'
Feb 4, 2026 09:01AM Arcellx presents data on anito-cel binder specificity at TANDEM meeting
Jan 21, 2026 04:00PM Arcellx presents anito-cel research at 2026 Tandem Meetings
Jan 7, 2026 12:37AM UBS Assumes Arcellx Inc. (ACLX) at Buy
Dec 22, 2025 05:59AM Wells Fargo Starts Arcellx Inc. (ACLX) at Overweight
Dec 22, 2025 05:48AM Arcellx (ACLX) call put ratio 1 call to 5.2 puts with a focus on May 40 puts
Dec 9, 2025 03:31PM Stifel: 'We’re Buyers of ACLX Here'
Dec 8, 2025 02:54AM Arcellx reports positive trial data for multiple myeloma treatment
Nov 25, 2025 07:42AM Stifel Reiterates Buy Rating on Arcellx (ACLX): ASH Presentation Awaited
Nov 24, 2025 02:20PM Guggenheim Defending on Arcellx Inc. (ACLX) Amid 17pct Drop
Nov 24, 2025 02:07PM Arcellx stock falls after Kelonia reveals promising blood cancer data
Nov 17, 2025 04:10PM Wolfe Research Starts Arcellx Inc. (ACLX) at Peerperform
Nov 5, 2025 06:00PM Arcellx, Inc. (ACLX) Misses Q3 EPS by 3c
Nov 3, 2025 06:36AM Arcellx Inc. (ACLX) PT Raised to $130 at Canaccord Genuity
Oct 16, 2025 04:54AM Stifel Starts Arcellx Inc. (ACLX) at Buy
Oct 9, 2025 08:04AM Cantor Fitzgerald Assumes Arcellx Inc. (ACLX) at Neutral
Jul 31, 2025 07:08AM Arcellx Inc. (ACLX) PT Raised to $133 at Scotiabank
Jul 8, 2025 08:23AM Piper Sandler Reiterates Overweight Rating on Arcellx Inc. (ACLX)
Jun 17, 2025 05:17AM Citi Starts Arcellx Inc. (ACLX) at Buy
Jun 16, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Arcellx Inc. (ACLX)
May 8, 2025 04:10PM Arcellx, Inc. (ACLX) Misses Q1 EPS by 37c
Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
Mar 20, 2025 04:00PM Arcellx (ACLX) Appoints Andrew Galligan and Kristin Myers to Its Board
Jan 27, 2025 09:31AM Stifel Reiterates Buy Rating on Arcellx Inc. (ACLX)
Jan 2, 2025 04:00PM Biotech outlook for 2025: Stifel
Jan 2, 2025 10:56AM Stifel Highlights Iovanace Biotherapeutics (IOVA) as 'Top Pick' in Biotech's 2025 Outlook Note
Dec 10, 2024 08:44AM Stifel Reiterates Buy Rating on Arcellx Inc. (ACLX) on Anito-Cel 'Best-in-Class' Potential
Dec 9, 2024 09:01AM TD Cowen Reiterates Buy Rating on Arcellx Inc. (ACLX), Cites 'Best-in-Class' Potential for Anito-Cel
Dec 9, 2024 08:09AM Arcellx Inc. (ACLX) PT Raised to $112 at BofA Securities
Nov 12, 2024 07:48AM Arcellx Inc. (ACLX) PT Raised to $136 at Truist Securities
Nov 8, 2024 07:19AM Arcellx Inc. (ACLX) PT Raised to $115 at Piper Sandler
Nov 8, 2024 06:54AM Arcellx, Inc. (ACLX) Misses Q3 EPS by 14c
Nov 6, 2024 07:23AM Piper Sandler Reiterates Overweight Rating on Arcellx Inc. (ACLX)
Nov 6, 2024 07:08AM Arcellx Inc. (ACLX) PT Raised to $106 at Baird
Nov 6, 2024 06:45AM Arcellx Inc. (ACLX) PT Raised to $95 at H.C. Wainwright
Nov 5, 2024 11:59AM Arcellx Inc. (ACLX) PT Raised to $100 at BofA Securities
Nov 5, 2024 09:01AM Arcellx (ACLX) to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma
Oct 29, 2024 06:06AM Arcellx Inc. (ACLX) PT Raised to $120 at Evercore ISI
Oct 18, 2024 07:22AM Arcellx Inc. (ACLX) PT Raised to $122 at Stifel
Oct 8, 2024 04:11AM Redburn-Atlantic Starts Arcellx Inc. (ACLX) at Buy
View Older Stories